David Ralph Email & Phone Number

US marketing launch lead for TLX101-CDx.

Chicago, Us

Responsible for the marketing functions related to the commercial launch of Cerianna in the United States. Established brand identity, led the development of the cross-functional brand plan, identified and developed KOLs, and executed on omni-channel tactical brand plans to grow demand 3-fold in 2022 and achieve 50% brand awareness.• Drove 2022 Cerianna demand growth >300%

Oxford, Gb

Marketing and commercial planning for the Glioma indication of Axumin. Responsible for building and managing a sales team, the development and execution of brain tumor sales training, market sizing and forecasting, qualitative and quantitative market research, message testing, brand and launch planning, identifying and developing key opinion leaders, driving cross-functional teams to execute to the launch plan, established partnerships with patient Advocacy Organizations, and life-cycle management for other CNS indications.

Global marketing leadership in Oncology, Neurology, and Women’s Health genetic testing to deliver on International market sizing and forecasting, business development for International lab partnerships, strategic planning and value proposition development, operational excellence for market access, and led product launches.

Omana (Ne), Nebraska, Us

Develop strategic direction, product positioning, and budgetary planning for the Neurology, Oncology, Pharmacogenetic, and Orthopedic testing lines. Develop strategic research partnerships, clinical study strategy and execution, KOL development, forecasting for new and existing tests, advocacy organization partnerships, new test launches and promotional materials, public relations, website development, audience segmentation, and pricing.

Marlborough, Ma, Us

Responsible for defining and executing key components of the Neurology testing portfolio in alignment with the strategic vision of the company and overall product roadmap. Taking input from the external stakeholders and internal cross-functional teams, drive product training, promotion, pricing, forecasting, KOL development, and commercialization strategy.

Worked closely with our co-promotion partner, Novartis Pharmaceuticals, to shape the hepatitis-B market and differentiate SEBIVO in a crowded market place. Focused on strategic planning, while delivering on tactical initiatives for the global launch of SEBIVO. Communicated with the country brand teams on their marketing needs and flawless execution to support their launches.

Us

Led the 2006 strategic market plan and the re-branding of TESTIM with our co-promotion partners Auxilium, the tactical programs included ad board meetings, Direct-to-Consumers through multiple channels, Direct-to-Physician, and Direct-to-Patient educational and promotional initiatives. Led the launch of FACTIVE5 with product positioning, branding, promotion, and commercial planning.

Paris, France, Fr

Initiated, created, & directed the Gaucher awareness direct-to-consumer campaigns. This multifaceted campaign – TV, radio, print, PR, educational symposia - was responsible for 10% of all new patient starts on CEREZYME therapy in the U.S. Developed and implemented direct to patient initiatives that improved adherence to therapy from 95% to 96%. Identified and developed advocacy relationships to enhance the awareness of Gaucher disease in targeted populations – those that have Gaucher and individuals that are at the greatest risk of having the disorder. US CEREZYME sales reached $311M in 2003 (103% of goal), $293M in 2002 (105% of goal) and in 2001, U.S. CEREZYME sales reached $270M (100% of goal). This product is the major revenue generator for Genzyme.

Mba, Business Administration And Management, General

Marketing Certificate - Graduate Studies, Marketing

Ba, History